William L Klein

List of Publications by Year
in descending order

44 papers	8,259 citations	159585 30 h-index	276875 41 g-index
46 all docs	46 docs citations	46 times ranked	9393 citing authors

#	Article	IF	Citations
1	Altered succinylation of mitochondrial proteins, APP and tau in Alzheimerâ€™s disease. Nature Communications, 2022, 13, 159.	12.8	42
2	An Essential Role for Alzheimerâ€™s-Linked Amyloid Beta Oligomers in Neurodevelopment: Transient Expression of Multiple Proteoforms during Retina Histogenesis. International Journal of Molecular Sciences, 2022, 23, 2208.	4.1	5
3	Identification of intraneuronal amyloid beta oligomers in locus coeruleus neurons of Alzheimerâ€™s patients and their potential impact on inhibitory neurotransmitter receptors and neuronal excitability. Neuropathology and Applied Neurobiology, 2021, 47, 488-505.	3.2	25
4	Induction of inverted morphology in brain organoids by vertical-mixing bioreactors. Communications Biology, 2021, 4, 1213.	4.4	13
5	Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6844-6854.	7.1	62
6	Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease. Frontiers in Neurology, 2019, 10, 1140.	2.4	46
7	The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a nonâ€human primate model of Alzheimer's disease. Journal of Pathology, 2018, 245, 85-100.	4.5	180
8	The Amyloid-Î² Oligomer Hypothesis: Beginning of the Third Decade. Journal of Alzheimer's Disease, 2018, 64, S567-S610.	2.6	572
9	Alzheimer's Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station. Yale Journal of Biology and Medicine, 2017, 90, 45-61.	0.2	23
10	Rifampicin is a candidate preventive medicine against amyloid-Î² and tau oligomers. Brain, 2016, 139, 1568-1586.	7.6	96
11	Effective anti-Alzheimer AÎ² therapy involves depletion of specific AÎ² oligomer subtypes. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e237.	6.0	39
12	Amyloid Î² oligomers in Alzheimerâ€™s disease pathogenesis, treatment, and diagnosis. Acta Neuropathologica, 2015, 129, 183-206.	7.7	490
13	Alzheimer's Disease-Like Pathology Induced by Amyloid-Î² Oligomers in Nonhuman Primates. Journal of Neuroscience, 2014, 34, 13629-13643.	3.6	189
14	Modeling Alzheimerâ€™s Disease with iPSCs Reveals Stress Phenotypes Associated with Intracellular AÎ² and Differential Drug Responsiveness. Cell Stem Cell, 2013, 12, 487-496.	11.1	652
15	Inhibition of Choline Acetyltransferase as a Mechanism for Cholinergic Dysfunction Induced by Amyloid-Î² Peptide Oligomers. Journal of Biological Chemistry, 2012, 287, 19377-19385.	3.4	77
16	Different Î²-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiology of Aging, 2012, 33, 825.e1-825.e13.	3.1	86
17	Insights into the mechanism of Alzheimerâ€™s Î²-amyloid aggregation as a function of concentration by using atomic force microscopy. Applied Physics Letters, 2012, 100, .	3.3	7
18	Amyloid-Î² and Tau Pathology of Alzheimer's Disease Induced by Diabetes in a Rabbit Animal Model. Journal of Alzheimer's Disease, 2012, 32, 291-305.	2.6	81

#	Article	IF	Citations
19	Synaptotoxic Amyloid-Î² Oligomers: A Molecular Basis for the Cause, Diagnosis, and Treatment of Alzheimer's Disease?. Journal of Alzheimer's Disease, 2012, 33, S49-S65.	2.6	112
20	A Mouse Model of Amyloid Î² Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal LossIn Vivo. Journal of Neuroscience, 2010, 30, 4845-4856.	3.6	348
21	Targeting Generation of Antibodies Specific to Conformational Epitopes of Amyloid β-Derived Neurotoxins. CNS and Neurological Disorders - Drug Targets, 2009, 8, 65-81.	1.4	29
22	Alzheimer's disease-type neuronal tau hyperphosphorylation induced by AÎ² oligomers. Neurobiology of Aging, 2008, 29, 1334-1347.	3.1	386
23	Monoclonal antibodies that target pathological assemblies of AÎ². Journal of Neurochemistry, 2007, 100, 23-35.	3.9	308
24	Synaptic targeting by AÎ² oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. , 2006, 2, 43-55.		103
25	Temporal Profile of Amyloid-Î² (AÎ²) Oligomerization in an in Vivo Model of Alzheimer Disease. Journal of Biological Chemistry, 2006, 281, 1599-1604.	3.4	342
26	Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2273-2276.	7.1	790
27	Synaptic Targeting by Alzheimer's-Related Amyloid Î² Oligomers. Journal of Neuroscience, 2004, 24, 10191-10200.	3.6	905
28	Femtomole Immunodetection of Synthetic and Endogenous Amyloid-Î² Oligomers and Its Application to Alzheimer's Disease Drug Candidate Screening. Journal of Molecular Neuroscience, 2003, 20, 305-314.	2.3	77
29	Alzheimer's disease-affected brain: Presence of oligomeric AÎ² ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10417-10422.	7.1	995
30	Self-Assembly of AÎ²₁₋₄₂into Globular Neurotoxins. Biochemistry, 2003, 42, 12749-12760.	2.5	511
31	Vaccination with soluble AÎ² oligomers generates toxicityâ€neutralizing antibodies. Journal of Neurochemistry, 2001, 79, 595-605.	3.9	309
32	Increased protein tyrosine phosphorylation in apoptotic neural cell death due to microtubule perturbations. Neurotoxicity Research, 2000, 2, 357-372.	2.7	0
33	Rapid impact of ?-amyloid on Paxillin in a neural cell line. , 1997, 50, 979-989.		23
34	Protein kinase C and F-actin are essential for stimulation of neuronal FAK tyrosine phosphorylation by G-proteins and amyloid beta protein. FEBS Letters, 1996, 386, 185-188.	2.8	40
35	CNS neuronal focal adhesion kinase forms clusters that co-localize with vinculin. Journal of Neuroscience Research, 1996, 46, 445-455.	2.9	27
36	Iron Levels Modulate Î±â€Secretase Cleavage of Amyloid Precursor Protein. Journal of Neurochemistry, 1995, 64, 307-315.	3.9	80

#	Article	IF	Citations
37	Phosphorylated Tau Epitope of Alzheimer's Disease Is Coupled to Axon Development in the Avian Central Nervous System. Experimental Neurology, 1993, 120, 106-113.	4.1	45
38	Cholinergic differentiation in neurogenic basal forebrain cultures. Journal of Neurobiology, 1992, 23, 252-269.	3.6	1
39	Transient expression of adheron molecules during chick retinal development. Journal of Neurobiology, 1992, 23, 720-738.	3.6	3
40	Muscarinic Acetylcholine Receptors from Avian Retina and Heart Undergo Different Patterns of Molecular Maturation. Journal of Neurochemistry, 1988, 50, 1403-1411.	3.9	9
41	Glycoprotein Properties of Muscarinic Acetylcholine Receptors from Bovine Cerebral Cortex. Journal of Neurochemistry, 1986, 46, 23-32.	3.9	30
42	Parallel Postnatal Development of Choline Acetyltransferase Activity and Muscarinic Acetylcholine Receptors in the Rat Olfactory Bulb. Journal of Neurochemistry, 1986, 46, 671-680.	3.9	30
43	Receptor-Mediated Increases in Phosphatidylinositol Turnover in Neuron-Like Cell Lines. Journal of Neurochemistry, 1983, 40, 547-554.	3.9	41
44	Specificity of Muscarinic Acetylcholine Receptor Regulation by Receptor Activity. Journal of Neurochemistry, 1981, 37, 1099-1108.	3.9	30